Artelo Biosciences Net Income
| ARTL Stock | USD 1.29 0.04 3.01% |
As of the 13th of February 2026, Artelo Biosciences shows the Risk Adjusted Performance of (0.07), standard deviation of 6.37, and Mean Deviation of 4.61. Artelo Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Artelo Biosciences market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Artelo Biosciences is priced correctly, providing market reflects its regular price of 1.29 per share. Given that Artelo Biosciences is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Artelo Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Artelo Biosciences' valuation are provided below:There are over one hundred nineteen available fundamental signals for Artelo Biosciences, which can be analyzed over time and compared to other ratios. We recommend to validate Artelo Biosciences' prevailing fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 4.8 M. The Enterprise Value is projected to slide to about 1.2 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -8.8 M | -8.4 M | |
| Net Loss | -6.7 M | -6.4 M | |
| Net Loss | -8.8 M | -8.4 M | |
| Net Loss | (3.51) | (3.68) |
Artelo | Net Income | Build AI portfolio with Artelo Stock |
Historical Net Income data for Artelo Biosciences serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Artelo Biosciences represents a compelling investment opportunity.
Latest Artelo Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Artelo Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Artelo Biosciences financial statement analysis. It represents the amount of money remaining after all of Artelo Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Artelo Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artelo Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.83 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Artelo Net Income Regression Statistics
| Arithmetic Mean | (3,729,792) | |
| Coefficient Of Variation | (112.97) | |
| Mean Deviation | 3,814,834 | |
| Median | (2,172,176) | |
| Standard Deviation | 4,213,386 | |
| Sample Variance | 17.8T | |
| Range | 10.1M | |
| R-Value | (0.90) | |
| Mean Square Error | 3.5T | |
| R-Squared | 0.82 | |
| Slope | (754,514) | |
| Total Sum of Squares | 284T |
Artelo Net Income History
Other Fundumenentals of Artelo Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Artelo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Artelo Biosciences is extremely important. It helps to project a fair market value of Artelo Stock properly, considering its historical fundamentals such as Net Income. Since Artelo Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artelo Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artelo Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Artelo Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Artelo Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Artelo Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Artelo Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Artelo Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Artelo Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Artelo Biosciences.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Artelo Biosciences on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Artelo Biosciences or generate 0.0% return on investment in Artelo Biosciences over 90 days. Artelo Biosciences is related to or competes with GT Biopharma, Protagenic Therapeutics, Psyence Biomedical, Revelation Biosciences, Lipella Pharmaceuticals, Scisparc, and Biomotion Sciences. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatmen... More
Artelo Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Artelo Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Artelo Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 41.63 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.3 |
Artelo Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Artelo Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Artelo Biosciences' standard deviation. In reality, there are many statistical measures that can use Artelo Biosciences historical prices to predict the future Artelo Biosciences' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (1.16) | |||
| Treynor Ratio | 2.67 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Artelo Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Artelo Biosciences February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 2.68 | |||
| Mean Deviation | 4.61 | |||
| Coefficient Of Variation | (1,068) | |||
| Standard Deviation | 6.37 | |||
| Variance | 40.59 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (1.16) | |||
| Treynor Ratio | 2.67 | |||
| Maximum Drawdown | 41.63 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.3 | |||
| Skewness | 0.9868 | |||
| Kurtosis | 3.86 |
Artelo Biosciences Backtested Returns
Artelo Biosciences secures Sharpe Ratio (or Efficiency) of -0.0563, which signifies that the company had a -0.0563 % return per unit of risk over the last 3 months. Artelo Biosciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Artelo Biosciences' Risk Adjusted Performance of (0.07), mean deviation of 4.61, and Standard Deviation of 6.37 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Artelo Biosciences are expected to decrease at a much lower rate. During the bear market, Artelo Biosciences is likely to outperform the market. At this point, Artelo Biosciences has a negative expected return of -0.37%. Please make sure to confirm Artelo Biosciences' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Artelo Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.43 |
Average predictability
Artelo Biosciences has average predictability. Overlapping area represents the amount of predictability between Artelo Biosciences time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Artelo Biosciences price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Artelo Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | -0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Artelo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Artelo Biosciences reported net income of (9.83 Million). This is 102.88% lower than that of the Pharmaceuticals sector and 114.03% lower than that of the Health Care industry. The net income for all United States stocks is 101.72% higher than that of the company.
Artelo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in net income category among its peers.
Artelo Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Artelo Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Artelo Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Artelo Biosciences' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 16 K | Tower Research Capital Llc | 2025-06-30 | 447 | Ubs Group Ag | 2025-06-30 | 89.0 | Citigroup Inc | 2025-06-30 | 9.0 | Bank Of America Corp | 2025-06-30 | 5.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 4.0 | Fmr Inc | 2025-06-30 | 1.0 | Susquehanna International Group, Llp | 2025-06-30 | 0.0 | Rothschild Investment, Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 |
Artelo Fundamentals
| Return On Equity | -4.36 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | 2.22 M | ||||
| Shares Outstanding | 2.02 M | ||||
| Shares Owned By Insiders | 0.47 % | ||||
| Shares Owned By Institutions | 1.63 % | ||||
| Number Of Shares Shorted | 110.41 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | (10.11 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 104 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | (19.50) X | ||||
| Target Price | 18.0 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 3.51 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 4.7 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Artelo Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Artelo Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Artelo Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Artelo Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.